Pub Date : 2025-10-10DOI: 10.1016/s2468-1253(25)00321-8
Rob Brierley
Section snippets
ABTECT 1 & 2
Data from two randomised trials indicate that the microRNA upregulator obefazimod resulted in significantly higher rates of clinical remission at week 8 than did placebo in patients with moderately-to-severely active ulcerative colitis. Both trials, presented by Bruce E Sands (New York City, NY, USA), randomly assigned participants to receive obefazimod 25 mg, obefazimod 50 mg, or placebo. At week 8, in the ABTECT 1 trial, 38 (24%) of 160 patients receiving obefazimod 25 mg, 69 (22%) of 318
TRIASSIC trial
For en-bloc resection of large, non-pedunculated rectal lesions, endoscopic submucosal dissection (ESD) is non-inferior to transanal minimally invasive surgery (TAMIS) in terms of local recurrence at 12 months, according to data presented by Nik Dekkers (Leiden, the Netherlands). In the multicentre, randomised TRIASSIC trial, patients with non-pedunculated rectal lesions larger than 2 cm that were located at most 15 cm from the anal verge were randomly assigned to undergo either ESD (n=100) or
WATERLAND trial
Fluid resuscitation with lactated Ringer's solution in patients with acute pancreatitis did not improve key clinical outcomes compared with normal saline, according to the results of the WATERLAND trial. In this randomised controlled trial presented by Enrique de-Madaria (Alicante, Spain), patients with acute pancreatitis were randomly assigned to receive fluid resuscitation with either lactated Ringer's (n=399) or normal saline (n=393) for at least 48 h. Although there was evidence that
The Mediterranean diet in irritable bowel syndrome
The Mediterranean diet could be a new first-line dietary option for patients with irritable bowel syndrome (IBS), according to data presented by Imran Aziz (Sheffield, UK). In a randomised non-inferiority trial, individuals with IBS were randomly assigned to follow the Mediterranean diet (n=68) or traditional dietary advice (n=71) for 6 weeks. The primary endpoint was the proportion of participants achieving clinical response (defined as a 50-point or greater reduction in the IBS Symptom
来自两项随机试验的数据表明，在中度至重度活动性溃疡性结肠炎患者中，microRNA上调剂obefazimod在第8周的临床缓解率显著高于安慰剂。这两项试验均由Bruce E Sands （New York City， NY， USA）提出，随机分配受试者接受奥贝法齐mod 25 mg、奥贝法齐mod 50 mg或安慰剂。第8周，在ABTECT 1试验中，160例患者中有38例（24%）接受了奥贝法莫25 mg， 318TRIASSIC试验中有69例（22%）。根据Nik Dekkers （Leiden, Netherlands）提供的数据，在12个月的局部复发率方面，内镜下粘膜下解剖（ESD）不低于经肛门微创手术（TAMIS）。在多中心随机TRIASSIC试验中，非带蒂直肠病变大于2 cm且位于肛门边缘最多15 cm的患者被随机分配进行ESD （n=100）或WATERLAND试验。根据WATERLAND试验的结果，与生理盐水相比，急性胰腺炎患者使用乳酸林格氏液进行液体复苏并没有改善关键临床结果。在这项由Enrique de-Madaria （Alicante, Spain）提出的随机对照试验中，急性胰腺炎患者被随机分配接受至少48小时的乳酸林格氏液（n=399）或生理盐水（n=393）液体复苏。尽管有证据表明，地中海饮食对肠易激综合征（IBS）患者可能是一种新的一线饮食选择。根据Imran Aziz （Sheffield， UK）提供的数据。在一项随机非劣效性试验中，肠易激综合征患者被随机分配到遵循地中海饮食（n=68）或传统饮食建议（n=71） 6周。主要终点是达到临床缓解的参与者比例（定义为IBS症状减少50分或以上）
{"title":"UEG Week 2025","authors":"Rob Brierley","doi":"10.1016/s2468-1253(25)00321-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00321-8","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>ABTECT 1 & 2</h2>Data from two randomised trials indicate that the microRNA upregulator obefazimod resulted in significantly higher rates of clinical remission at week 8 than did placebo in patients with moderately-to-severely active ulcerative colitis. Both trials, presented by Bruce E Sands (New York City, NY, USA), randomly assigned participants to receive obefazimod 25 mg, obefazimod 50 mg, or placebo. At week 8, in the ABTECT 1 trial, 38 (24%) of 160 patients receiving obefazimod 25 mg, 69 (22%) of 318</section></section><section><section><h2>TRIASSIC trial</h2>For en-bloc resection of large, non-pedunculated rectal lesions, endoscopic submucosal dissection (ESD) is non-inferior to transanal minimally invasive surgery (TAMIS) in terms of local recurrence at 12 months, according to data presented by Nik Dekkers (Leiden, the Netherlands). In the multicentre, randomised TRIASSIC trial, patients with non-pedunculated rectal lesions larger than 2 cm that were located at most 15 cm from the anal verge were randomly assigned to undergo either ESD (n=100) or</section></section><section><section><h2>WATERLAND trial</h2>Fluid resuscitation with lactated Ringer's solution in patients with acute pancreatitis did not improve key clinical outcomes compared with normal saline, according to the results of the WATERLAND trial. In this randomised controlled trial presented by Enrique de-Madaria (Alicante, Spain), patients with acute pancreatitis were randomly assigned to receive fluid resuscitation with either lactated Ringer's (n=399) or normal saline (n=393) for at least 48 h. Although there was evidence that</section></section><section><section><h2>The Mediterranean diet in irritable bowel syndrome</h2>The Mediterranean diet could be a new first-line dietary option for patients with irritable bowel syndrome (IBS), according to data presented by Imran Aziz (Sheffield, UK). In a randomised non-inferiority trial, individuals with IBS were randomly assigned to follow the Mediterranean diet (n=68) or traditional dietary advice (n=71) for 6 weeks. The primary endpoint was the proportion of participants achieving clinical response (defined as a 50-point or greater reduction in the IBS Symptom</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"1 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-08DOI: 10.1016/s2468-1253(25)00235-3
Alberto Pilotto, Carlo Custodero, Lucilla Crudele, Wanda Morganti, Nicola Veronese, Marilisa Franceschi
Disorders of the gastrointestinal tract are common in those aged 65 years or older, impairing their quality of life and potentially increasing morbidity and mortality risk. Unlike many organ systems, the luminal gastrointestinal tract does not undergo much natural degeneration. However, age-related anatomical and functional changes of the gastrointestinal tract might promote pathophysiology and explain some atypical presentations of gastrointestinal disorders in older adults. This Review summarises current knowledge of major anatomical and functional changes that occur in the gastrointestinal tract during ageing. These changes are often more evident in older adults who are frail or multimorbid, and frailty in older age might also influence the presentation, prognosis, and management of older patients with gastrointestinal disorders.
{"title":"Age-related changes of the gastrointestinal tract","authors":"Alberto Pilotto, Carlo Custodero, Lucilla Crudele, Wanda Morganti, Nicola Veronese, Marilisa Franceschi","doi":"10.1016/s2468-1253(25)00235-3","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00235-3","url":null,"abstract":"Disorders of the gastrointestinal tract are common in those aged 65 years or older, impairing their quality of life and potentially increasing morbidity and mortality risk. Unlike many organ systems, the luminal gastrointestinal tract does not undergo much natural degeneration. However, age-related anatomical and functional changes of the gastrointestinal tract might promote pathophysiology and explain some atypical presentations of gastrointestinal disorders in older adults. This Review summarises current knowledge of major anatomical and functional changes that occur in the gastrointestinal tract during ageing. These changes are often more evident in older adults who are frail or multimorbid, and frailty in older age might also influence the presentation, prognosis, and management of older patients with gastrointestinal disorders.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"116 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-08DOI: 10.1016/s2468-1253(25)00292-4
Sadé L Assmann, Daniel Keszthelyi, Merel L Kimman, Stéphanie O Breukink
No Abstract
没有抽象的
{"title":"Refining the faecal incontinence core outcome set – Authors' reply","authors":"Sadé L Assmann, Daniel Keszthelyi, Merel L Kimman, Stéphanie O Breukink","doi":"10.1016/s2468-1253(25)00292-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00292-4","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"19 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-08DOI: 10.1016/s2468-1253(25)00264-x
Oliver Old, Paul Moayyedi, Janusz Jankowski, Stephen Attwood, M Sofia Massa, Alex Zimmermann, Hugh Barr
No Abstract
没有抽象的
{"title":"Lessons learned from the BOSS trial","authors":"Oliver Old, Paul Moayyedi, Janusz Jankowski, Stephen Attwood, M Sofia Massa, Alex Zimmermann, Hugh Barr","doi":"10.1016/s2468-1253(25)00264-x","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00264-x","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"114 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：